PATENT CLAIM ANALYSIS

Application Number: 15873416
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-12
Patent Classification: ["514", "001100"]

Abstract:
The disclosure provides compositions and methods for counteracting the effects of direct activated Factor X (FXa) inhibitors in a subject by administering a variant of FXa.

Claim (Index 1):
A method for reversing the anticoagulant effect of a direct Factor Xa inhibitor in a subject, comprising administering to said subject a Factor Xa variant that contains at least one modification selected from the group consisting of:\n a) the amino acid at the position corresponding to 235 in SEQ ID NO:1 is substituted with Thr, Leu, Phe, Asp or Gly; and b) the amino acid at the position corresponding to 236 in SEQ ID NO:1 is substituted with Leu, Ala, or Gly.

Metadata:
- Claim Count in Document: 21.0
- Percentile: 86.0
- Lexical Diversity: 1.11538
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['12616735', '13414499', '13889014', '12239651', '13591098']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7824628285579781
- 35 USC 102 Novelty (BERT): 0.5226630043854085
- Combined Prediction Score: 0.7564828461407211
- Mean Citation Score: 318.84791800000005
- Max Citation Score: 322.3307200000001
- Similarity Product: 204.9756830861474

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 0
- Label 101 Adjusted: 1

Dataset: test